Patents Assigned to The Administrators of the Tulane
-
Patent number: 5485230Abstract: A system and method are described for determining a subject's perceived motion ability utilizing chromatic pathways. The equiluminant point between two selected colors is determined and two similar moving patterns are then provided, one equiluminant and the other luminant, the moving patterns consisting of only the two selected colors. The velocity of one pattern is held fixed while the velocity of the other pattern is matched to the fixed velocity by the subject. The difference between the matched velocity and the fixed velocity provides a measurement of the subject's perceived motion ability along the chosen chromatic pathways as compared to a standard. The comparison shows how to enhance motion perception ability by modifying the spectrum of the light impinging the subject's eyes in accordance with the comparison findings.Type: GrantFiled: May 3, 1993Date of Patent: January 16, 1996Assignee: The Administrators of the Tulane Educational FundInventor: George L. Zimmerman
-
Patent number: 5480969Abstract: LHRH antagonists similar to antide and congeners with higher water solubility have been synthesized by substitutions in positions 1, 5 or 6 with hydrophilic residues. These peptides have antiovulatory activity with minimal histamine releasing effect.Type: GrantFiled: September 15, 1992Date of Patent: January 2, 1996Assignees: The Administrators of the Tulane Educational Fund, Board of Regents, The University of Texas SystemInventors: Cyril Y. Bowers, Karl A. Folkers, Anders Ljungqvist, Dong-Mei Feng, Anna Janceka
-
Patent number: 5470947Abstract: Antide is the decapeptide, N--Ac--D--2--Nal,D--pClPhe, D--3--Pal, Ser,NicLys, D--NicLys, Leu, ILys, Pro, D--Ala,NH.sub.2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This decapeptide, like others of the present invention, has high antiovulatory activity (AOA) and releases negligible histamine. Antide is scheduled for scale-up, safety testing and evaluation in the experimental primate and in clinical medicine. Numerous other peptides having structures related to Antide were prepared and tested. These peptides had variations primarily in positions 5, 6, 7, and 8. Of these, N--Ac--D--2--Nal, D--pClPhe,D--3--Pal,Ser,PicLys,cis--DpzACAla, Leu,ILys,pro,D--Ala--NH.sub.2 was one of the most potent and had higher antiovulatory activity than Antide, i.e. 73%/0.25 ug and 100%/0.5 ug vs. 36%/0.5 ug and 100%/1.0 ug. Antide showed significant, (p<0.001) duration of action, when injected at a dose of 10 ug, 44 hours before 50 ng of the agonist, [D--3--Qal.sup.6 ]--LHRH.Type: GrantFiled: June 26, 1989Date of Patent: November 28, 1995Assignees: Board of Regents, The University of Texas System, The Administrators of the Tulane Educational FundInventors: Karl A. Folkers, Anders Ljungqvist, Dong-Mei Feng, Minoru Kubota, Pui-Fun L. Tang, Cyril Y. Bowers
-
Patent number: 5462926Abstract: A method of selectively inhibiting biochemical activity of cells induced by neuromedin B. The method includes the step of contacting cells which contain neuromedin B receptor with a cyclic octapeptide, D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH.sub.2, or an analog thereof.Type: GrantFiled: June 17, 1993Date of Patent: October 31, 1995Assignees: Biomeasure, Inc., Administrators of the Tulane Educational FundInventors: David H. Coy, John E. Taylor
-
Patent number: 5462927Abstract: Biologically active peptides are disclosed of the formula: A.sup.1 --A.sup.2 --A.sup.3 --A.sup.4 --Phe--Arg--TrP--A.sup.5, or a pharmaceutically acceptable salt thereof; A.sup.1 is H or acetyl; A.sup.2 is Ala, or D--Ala; A.sup.3 is Glu or Gln; and A.sup.4 is His or Tyr; A.sup.5 is NH.sub.2, Gly--NH.sub.2, or D--Ala--NH.sub.2. Pharmaceutical compositions containing these peptides are capable of promoting nerve regeneration and increasing muscle mass or preventing muscle atrophy following an injury.Type: GrantFiled: December 14, 1992Date of Patent: October 31, 1995Assignee: The Administrators of the Tulane Educational FundInventors: Jacques-Pierre Moreau, David H. Coy
-
Patent number: 5456911Abstract: The present invention includes novel peptides GQDEGEENEG, SEQ. ID NO:1 GRNGLGANTDQDDQLEDE, SEQ. ID NO:2 DQFFDANPNLFQLLEPVEFDED, SEQ. ID NO:3 and LVFLVQQPFLFVLWDQNEKFPVFMGVYDP SEQ. ID NO:3. Such peptides are useful for detecting antibodies against circulating malarial antigens. In one aspect, these peptides may be copolymerized or crosslinked to form immunogens presenting epitopes of the malarial Plasmodium falciparum antigen Pf70. Preferably at least two of the above peptides are so crosslinked. Most preferably, all four peptides are copolymerized. The crosslinking agent preferred is glutaraldehyde although, of course, other crosslinking agents such as dialdehydes of various lengths, for example, or even possibly the carbodiimides may be used. Compositions of matter comprising such peptides in crosslinked or copolymerized forms are an important part of the present invention, particularly when used as immunogens. Rabbits have been immunized with a composition of the four crosslinked peptides at a dose of 2.Type: GrantFiled: January 15, 1993Date of Patent: October 10, 1995Assignee: The Administrators of the Tulane Educational FundInventors: Mark A. James, Sonia Montenegro-James
-
Patent number: 5410019Abstract: A linear peptide which is an analog of naturally occurring, biologically active substance P having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. The analog has a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue, or a synthetic, a .beta.-amino acid, or a .alpha.-amino acid residue replacing two amino acid residues of the active site.Type: GrantFiled: March 30, 1992Date of Patent: April 25, 1995Assignee: The Administrators of the Tulane-Educational FundInventors: David H. Coy, Jacques-Pierre Moreau
-
Patent number: 5369094Abstract: Pseudopeptides comprising a peptide of formula I:X-A.sup.1 -A.sup.2 -Trp-Ala-Val-Gly-His-Leu-.sub.psi -A.sup.9 -Qwherein X is hydrogen, a single bond linking the alpha amino group of A.sup.1 to the gamma carboxyl moiety on the 3-priopionyl moiety of A.sup.2 when A.sup.2 is Glu, or a group of formula R.sup.1 CO-- wherein R.sup.1 is selected from the groups consisting ofa) hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.1-10 -alkyl, p-HI-phenyl, p-HI-phenyl-C.sub.1-10 -alkyl, naphthyl, naphthyl-C.sub.1-10 -alkyl, indolyl, indolyl-C.sub.1-10 -alkyl, pyridyl, pyridyl-C.sub.1-10 -alkyl, thienyl, thienyl-C.sub.1-10 -alkyl, cyclohexyl or cyclohexyl-C.sub.1-10 -alkyl, where HI=F, Cl, Br, OH, CH.sub.3 or OCH.sub.3 ;b) N(R.sup.2)(R.sup.3)--, wherein R.sup.2 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.1-10 -alkyl, R.sup.3 is hydrogen or C.sub.1-10 alkyl; c) R.sup.4 O--, wherein R.sup.4 is C.sub.1-10 alkyl, phenyl or phenyl-.sub.1-10 -alkyl; A.sup.Type: GrantFiled: March 15, 1993Date of Patent: November 29, 1994Assignee: The Administrators of the Tulane Educational FundInventors: Andrew V. Schally, Renzhi Cai
-
Patent number: 5364757Abstract: The present invention relates to the discovery of a novel retroviral particle associated with autoimmune disease. New methods of diagnosis and treatment of autoimmune disease, novel cell lines comprising the new retrovirus, assay systems that may be used in the development of antiretroviral pharmaceuticals, and model systems for the study of autoimmune diseases and acquired immunodeficiency syndrome (AIDS) are provided by the present invention.Type: GrantFiled: December 11, 1991Date of Patent: November 15, 1994Assignee: Administrators of the Tulane Educational FundInventors: Robert F. Garry, Jr., Cesar D. Fermin, Steve S. Alexander, Jr.
-
Patent number: 5344774Abstract: The present invention relates to purified preparations of a novel retrovirus, to methods of diagnosis and treatment of Sjogren's syndrome, novel cell lines, and model systems for the study of autoimmune diseases and AIDS. It is based, in part, on the discovery of a novel retrovirus which is antigenically similar to human immunodeficiency virus but which appears to comprise a functionally distinct reverse transcriptase.According to the present invention, Sjogren's syndrome as well as other autoimmune diseases, may be diagnosed, and their clinical course may be monitored, by demonstrating the presence of anti-retroviral antibodies and/or measuring the levels of such antibodies. Alternatively, Sjogren's syndrome or other autoimmune diseases may be diagnosed or monitored by directly or indirectly demonstrating vital particles in the cells of a patient.Type: GrantFiled: February 23, 1993Date of Patent: September 6, 1994Assignee: The Administrators of the Tulane Educational FundInventors: Robert F. Garry, Jr., Cesar D. Fermin, Steve S. Alexander, Jr.
-
Patent number: 5324436Abstract: A process is disclosed for regulating the size and composition of the internal reaction medium of a membrane mimetic system using clathrate hydrate formation under gas pressure conditions. When the disclosed membrane mimetic system is in contact with a clathrate forming gas, some of the water in the internal reaction medium is converted to crystalline hydrate form, which physically and chemically isolates the water from the remainder of the internal reaction medium. In one preferred process embodiment, the membrane mimetic system is used for enzymatic polymer synthesis in an organized medium to control the size and morphology of the polymer particles formed.Type: GrantFiled: March 12, 1993Date of Patent: June 28, 1994Assignee: The Administrators of the Tulane Educational FundInventors: Vijay T. John, Joseph A. Akkara, David L. Kaplan
-
Patent number: 5281341Abstract: A method of treating a liquid waste or process stream that includes a sludge component and that enhances sludge treatment or stabilization. The sludge is acidified to a pH of less than 4.0 in an oxygen enriched environment. A nitrous acid level is maintained sufficiently high to kill pathogens, in a closed chamber so that the nitrous acid won't be lost from the chamber through volatilization.Type: GrantFiled: August 9, 1991Date of Patent: January 25, 1994Assignee: Administrators of the Tulane Educational FundInventors: Robert S. Reimers, Maurice D. Little
-
Patent number: 5280457Abstract: A detecting system and method of determining the position of a mobile point of interest in a m dimensional coordinate system having an ultrasonic transmitter mounted on the point of interest, and a plurality of stationary ultrasonic receivers, the number being at least m plus 2. The location of the receivers are determined optimally by using a linear matrix formulation. Alternatively, the location of the receivers can be determined during installation or self-calibration of the system. The system also includes receiver controlling means for processing the received signal to generate time of flight measurements which are used to eliminate the speed of sound as a variable and to compute the location of the point of interest. The controlling means also generates phase measurements when prompted by an outside source by comparing the transmitted signal with a 40kHz pulse sync to refine the accuracy of the location of the point of interest.Type: GrantFiled: July 31, 1992Date of Patent: January 18, 1994Assignee: The Administrators of the Tulane Educational FundInventors: Jorge F. Figueroa, Enrique Barbieri
-
Patent number: 5267940Abstract: An implanted cardiovascular assist pump is connected with the proximal descending thoracic aorta. The pump inlet is connected with the aorta at substantially the site of the first pressure/flow node from the heart. The pump outlet is connected at substantially the site of the last pressure/flow antinode before the heart. Control of pump speed varies blood flow through the pump. As a fail-safe mechanism, a pump shunt flow path is provided, through one of a variety of disclosed structures.Type: GrantFiled: May 6, 1991Date of Patent: December 7, 1993Assignee: The Administrators of the Tulane Educational FundInventor: Peter V. Moulder
-
Patent number: 5258492Abstract: The present invention deals with LHRH analogues which contain cytotoxic moieties and have influence on the release of gonadotropins from the pituitary gland of mammals, including humans. The compounds of this invention are represented by the formula:X--R.sup.1 --R.sup.2 --R.sup.3 -Ser-R.sup.5 --R.sup.6 (Q)-Leu-Arg-Pro-R.sup.10 --NH.sub.2whereinR.sup.1 is pGlu, Pro, D-Nal(2), or D-Phe(4Cl),R.sup.2 is His or D-Phe(4Cl),R.sup.3 is Trp, D-Trp or D-Pal(3),R.sup.5 is Tyr or Arg,R.sup.6 is D-Phe or R*.sup.6, where R*.sup.6 is D-Orn, D-Lys or D-Phe(NH.sub.2),R.sup.10 is Gly or D-Ala,X is hydrogen, a lower alkanoyl group of 2-5 carbon atoms or carbamyl,Q is bis-(2-chloroethyl)amino group provided that R.sup.6 is D-Phe,where R.sup.6 is R*.sup.6,Q is a complexed metal-containing acyl group having the formula: ##STR1## wherein Q' is Pt(Y).sub.Type: GrantFiled: June 3, 1991Date of Patent: November 2, 1993Assignee: The Administrators of the Tulane Educational FundInventors: Andrew V. Schally, Sandor Bajusz
-
Patent number: 5244883Abstract: The novel pseudo polypeptides of this invention are potent bombesin antagonists. There are provided processes for their production, pharmaceutical compositions comprising said polypeptides and their use as pharmaceutically active agents. More particularly the present invention provides pseudopeptides comprising a nonapeptide moiety of formula I:X-A.sup.1 -A.sup.2 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -.sub.psi -A.sup.9 -Qwherein Q is NH.sub.2 or OQ.sup.1 where Q.sup.1 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.7-10 alkyl; X is hydrogen or a single bond linking to A.sup.2 the acyl residue of an organic acid, or a group of formula R.sup.1 CO-- wherein (1) R.sup.1 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.7-10 -alkyl; (2) R.sup.1 CO-- is (a) R.sup.2 N(R.sup.3)--CO-- wherein R.sup.2 is hydrogen, C.sub.1-10 alkyl, phenyl or C.sub.7-10 phenyl-C.sub.7-10 -alkyl, R.sup.3 is hydrogen or C.sub.1-10 alkyl; (b) R.sup.4 --O--CO-- wherein R.sup.4 is C.sub.Type: GrantFiled: November 29, 1990Date of Patent: September 14, 1993Assignee: The Administrators of the Tulane Educational FundInventors: Renzhi Cai, Andrew V. Schally
-
Patent number: 5232700Abstract: A piracetam-containing preparation is applied to prevent and/or treat recurrent herpetic lesions. When used prophylactically, the piracetam-containing preparation is applied during the prodromal phase of a herpes recurrence at the site of previous eruptions. When used for treatment purposes, the piracetam-containing preparation is initially applied within six to twelve hours of the appearance of the herpetic lesions and application is continued at set intervals until the lesions disappear.Type: GrantFiled: November 14, 1990Date of Patent: August 3, 1993Assignee: The Administrators of the Tulane Educational FundInventor: Ysolina Centifanto
-
Patent number: 5198533Abstract: The present invention deals with LHRH antagonists which possess improved water solubility and while having the high antagonist potency of the basic peptides, are free of the edematogenic effects. These compounds are highly potent in inhibiting the release of gonadotropins from the pituitary gland in mammals, including humans.The compounds of this invention are represented by the formulaX--R.sup.1 --R.sup.2 --R.sup.3 --Ser--Tyr--R.sup.6 --Leu--Arg--Pro--R.sup.10 --NH.sub.2whereinX is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, or H.sub.2 N--CO,R.sup.1 is D-- or L--Pro, D-- or L--.DELTA..sup.3 --Pro, D--Phe, D--Phe(4--H1), D--Ser, D--Thr, D--Ala, D--Nal(1) or D--Nal (2),R.sup.2 is D--Phe or D--Phe(4--C1)R.sup.3 is D--Trp, D--Phe, D--Pal(3), D--Nal(1) or D--Nal(2),R.sup.6 is D--Cit, D--Hci, D--Cit(Q) or D--Hci(Q) andR.sup.Type: GrantFiled: May 23, 1988Date of Patent: March 30, 1993Assignee: The Administrators of the Tulane Educational FundInventors: Andrew V. Schally, Sandor Bajusz
-
Patent number: 5171835Abstract: Disclosed herein are analogues of the luteinizing hormone-releasing hormone (LH-RH), which are potent antagonists of LH-RH. These peptides inhibit the release of gonadotropins from the pituitary in mammals, including humans and possess antitumor activity.Formula I represents peptides which are within the scope of this invention:X--R.sup.1 --R.sup.2 --R.sup.3 --Ser--R.sup.5 --R.sup.6 (AY.sub.2)--Leu--Arg--Pro--D--Ala--NH.sub.2 Iand the pharmaceutically acceptable salts thereof, whereinR.sup.1 is D-Phe, D-Phe(4Cl), D-Nal(1) or D-Nal(2),R.sup.2 is D-Phe or D-Phe(4HI),R.sup.3 is D-Trp, D-Phe, D-Phe(4HI), D-Nal(1), D-Nal(2) or D-Pal(3),R.sup.5 is Tyr or Arg,R.sup.6 is D-Lys or D-Orn,HI is fluoro, chloro or bromoX is a lower alkanoyl group of 2-5 carbon atoms,A is a diaminoacyl residue having the formula ##STR1## where m is 0 or 1,n is 0 or 1,Y is Y.sup.1 or Y.sup.2, whereinY.sup.Type: GrantFiled: January 30, 1991Date of Patent: December 15, 1992Assignee: The Administrators of the Tulane Educational FundInventors: Tamas Janaky, Atilla Juhasz, Andrew V. Schally
-
Patent number: 5162497Abstract: A bradykinin analog which contains nine or ten amino acid residues and at least one [CH.sub.2 NH] pseudopeptide bond, the analog being useful as an antagonist or agonist of the naturally occuring bradykinin.Type: GrantFiled: December 9, 1988Date of Patent: November 10, 1992Assignee: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jacques-Pierre Moreau, John E. Taylor, Sun H. Kim